Table 3.
Plasma biomarkers in patients with Kawasaki disease who had a response to IVIG or were IVIG resistant.
| Biomarker | Response (n = 58) | Resistance (n = 5) |
P value |
|---|---|---|---|
| CLUSTER 1 | 25.02 ± 12.33 | 16.44 ± 6.59 | 0.132 |
| CLUSTER 2 | 23.09 ± 12.59 | 27.70 ± 10.14 | 0.429 |
| CLUSTER 12 | −1.93 ± 13.66 | 11.26 ± 11.17 | 0.040* |
| CLUSTER 012 | 1.33 ± 0.90 | 0.64 ± 0.35 | 0.097 |
| FIB 1 | 1141.68 ± 795.77 | 803.94 ± 185.89 | 0.351 |
| FIB 2 | 1513.52 ± 1122.97 | 1258.25 ± 946.08 | 0.624 |
| FIB 12 | 371.85 ± 726.86 | 454.31 ± 895.55 | 0.812 |
| FIB 012 | 0.83 ± 0.34 | 0.82 ± 0.31 | 0.934 |
CLUSTER 1 (mg/L): plasma clusterin concentration before IVIG treatment; CLUSTER 2 (mg/L): plasma clusterin concentration after IVIG treatment; CLUSTER 12 (mg/L): CLUSTER 2 − CLUSTER 1; CLUSTER 012: CLUSTER 2/CLUSTER 1; FIB 1 (mg/dL): plasma fibrinogen concentration before IVIG treatment; FIB 2 (mg/dL): plasma fibrinogen concentration after IVIG treatment; FIB 12 (mg/dL): FIB 2 – FIB 1; FIB 012: FIB 2/FIB 1. *P < 0.05 was considered statistically significant difference.